Global Mycophenolate Mofetil Market By Size, Demand Analysis, Type, Statistics, Regions and Forecast – 2028

The global mycophenolate mofetil market is anticipated to grow at a significant CAGR 2% during the forecast period (2022-2028). Mycophenolate belongs to a class of medicine known as immunosuppressants that is usually administered in combination with other medications so as to prevent the body from attacking and rejecting the transplanted organ which could be liver, kidney, or even heart. Mycophenolate mofetil is considered to be an effective inhibitor of lymphocyte proliferation and is generally used to prevent acute rejection of allografts. Mycophenolate mofetil is also widely used as a glucocorticoid reducing agent in the treatment of various rheumatic diseases such as inflammation myopathy, systemic sclerosis, systemic lupus erythematosus, as well as some systemic vasculitis. The global mycophenolate mofetil market growth is majorly attributable to the growing prevalence of inflammation myopathy, systemic sclerosis, systemic lupus erythematosus, as well as some systemic vasculitis among the global population.

There are various types of mycophenolate mofetil available in the market in the form of tablets, capsules, injection and suspension. Increased demand for high-quality capsules in the pharmaceuticals and healthcare industry is likely to drive their demand across the globe. As per the National Center for Biotechnology Information (NCBI), owing to the availability of novel immunosuppressants such as mycophenolate mofetil, incidence of acute graft rejection has decreased. It has been found to be useful in preventing as well as treating chronic and acute rejection after transplantation. Besides transplant it has been used successfully in primary and secondary glomerulopathies such as systemic lupus erythematosus and other autoimmune diseases.

Some key players operating in the market include Novartis International AG, Mylan NV, and Teva Pharmaceutical Industries Ltd., among others. The market players are focusing on new product launches, mergers and acquisitions, and partnerships and collaborations. For instance, in December 2020, Lupin Ltd. declared the launch of Mycophenolate Mofetil Tablets USP, 500 mg, after Lupin’s alliance partner Concord Biotech Ltd. (Concord) received an approval for its ANDA from the US Food and Drug Administration. Mycophenolate Mofetil Tablets USP, 500 mg, are the generic equivalent of CellCept Tablets of Roche Palo Alto LLC, indicated for the prophylaxis of organ rejection in recipients of allogeneic kidney, heart or liver transplants, and should be used in combination with other immunosuppressants.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-

• By Type
• By Application

• Regions covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape: Novartis International AG, Mylan NV, and Teva Pharmaceutical Industries Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

• Deviation from the pre-COVID-19 forecast
• Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Mycophenolate Mofetil Market Report by Segment

By Type

• Capsule
• Tablet
• Injection

By Application

• Heart Transplant
• Kidney Transplant
• Liver Transplant
• Others

Global Mycophenolate Mofetil Market Report by Region

North America

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa